Eiry Roberts - Feb 12, 2025 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
Feb 12, 2025
Transactions value $
-$258,264
Form type
4
Date filed
2/14/2025, 06:42 PM
Previous filing
Feb 12, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +2.11K +6.35% $0.00 35.4K Feb 13, 2025 Direct
transaction NBIX Common Stock Sale -$130K -1.11K -3.15% $116.90 34.3K Feb 13, 2025 Direct F1, F2
transaction NBIX Common Stock Options Exercise $0 +1.12K +3.27% $0.00 35.4K Feb 13, 2025 Direct
transaction NBIX Common Stock Sale -$70.5K -604 -1.71% $116.74 34.8K Feb 13, 2025 Direct F3, F4
transaction NBIX Common Stock Options Exercise $0 +1.37K +3.95% $0.00 36.1K Feb 13, 2025 Direct
transaction NBIX Common Stock Sale -$57.5K -500 -1.38% $115.04 35.6K Feb 14, 2025 Direct F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Stock Option Award $0 +43.3K $0.00 43.3K Feb 12, 2025 Common Stock 43.3K $117.18 Direct F7
transaction NBIX Restricted Stock Unit Award $0 +8.11K $0.00 8.11K Feb 12, 2025 Common Stock 8.11K Direct F8, F9
transaction NBIX Restricted Stock Unit Options Exercise $0 -2.11K -33.33% $0.00 4.23K Feb 13, 2025 Common Stock 2.11K Direct F8, F10
transaction NBIX Restricted Stock Unit Options Exercise $0 -1.12K -24.98% $0.00 3.36K Feb 13, 2025 Common Stock 1.12K Direct F8, F11
transaction NBIX Restricted Stock Unit Options Exercise $0 -1.37K -25% $0.00 4.12K Feb 13, 2025 Common Stock 1.37K Direct F8, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.24 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F4 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $118.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.76 to $115.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 34,455 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
F7 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F8 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
F9 The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.
F10 This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, and will vest as to 2,113 shares on February 13, 2026, and 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.
F11 This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, and will vest as to 1,121 shares on February 13, 2026, 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.
F12 This RSU was granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, and will vest as to 1,372 shares on February 13, 2026, 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.